Metabolon Identifies Preterm Labor Biomarkers
RESEARCH TRIANGLE PARK, N.C. (July 02, 2010)— Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, announces the publication of “Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery”, in The Journal of Maternal-Fetal and Neonatal Medicine.
The study, carried out in collaboration with co-authors Dr. Roberto Romero and colleagues of the NICHD, NIH, and DHHS, aimed to identify prognostic and diagnostic biomarkers of preterm delivery in women with spontaneous preterm labor (PTL) and intact membranes. Spontaneous preterm labor does not always lead to preterm delivery and the accurate and rapid identification of the risk of preterm delivery to pregnant women with PTL is needed for physicians to make immediate patient management decisions. The report describes the identification of biomarkers for PTL and delivery and concludes that the risk of preterm delivery, in the presence or absence of infection and inflammation, can be assessed by metabolic profiling of amniotic fluid. In addition, the report presents a preliminary draft of the human amniotic fluid metabolome from women with PTL that shows biochemical intermediates of human metabolism as well as xenobiotics such as salicylamide and bacterial products can be measured in human amniotic fluid.
Copies of the paper can be accessed through the Journal of Maternal-Fetal and Neonatal Medicine by clicking here or, alternatively, copy and pasting the link below into your web browser: http://informahealthcare.com/doi/abs/10.3109/14767058.2010.482618
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske email@example.com at (919) 595-2200.